{"name":"Rezolute","slug":"rezolute","ticker":"RZLT","exchange":"NASDAQ","domain":"rezolutebio.com","description":"Rezolute is a biopharmaceutical company focused on developing treatments for rare endocrine disorders. The company's pipeline includes RZ358, a treatment for congenital hyperinsulinism, and RZ402, a treatment for congenital adrenal hyperplasia. Rezolute's top drugs are RZ358 and RZ402, which are currently in various stages of clinical development. The company is well-positioned to capitalize on the growing market for rare disease treatments.","hq":"Redwood City, CA","founded":0,"employees":"","ceo":"Nevan Elam","sector":"Rare Disease / Endocrinology","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"$120M","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":61527000,"netIncome":-74412000,"cash":94107000,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2034-06-01","label":"RZ358 patent cliff ($X.XB at risk)","drug":"RZ358","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[{"date":"2024-02-28","type":"earnings","headline":"Rezolute Reports Fourth Quarter and Full Year 2023 Financial Results","summary":"Rezolute reported its fourth quarter and full year 2023 financial results, including revenue of $X.X million and a net loss of $Y.Y million.","drugName":"","sentiment":"neutral"},{"date":"2023-11-15","type":"deal","headline":"Rezolute Announces Collaboration with University of California, San Francisco","summary":"Rezolute announced a collaboration with the University of California, San Francisco to develop new treatments for rare endocrine disorders.","drugName":"","sentiment":"positive"},{"date":"2023-08-01","type":"trial","headline":"Rezolute Initiates Phase 3 Clinical Trial for RZ358","summary":"Rezolute initiated a Phase 3 clinical trial for RZ358, a treatment for congenital hyperinsulinism.","drugName":"","sentiment":"neutral"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi_AFBVV95cUxPZUtQcmhYSVRreVdXLTVSNWlBd2JXOUd6NVBwWEI5MHQ4aUU4YmFVTUpNa2pyQXJOOFZqQkVXX09KR0o5ekNQaUl5bkVFQ3MzUG1JUFl2c183RWpITFpZaFJVbmplbjZiS3c4d1RLek5nQU0wb2tXSm5fakpfcVBsdEoxQ09tb2cyOEpWaEVPXzNmNDhIaG1yeHZvUlBseXlJRG84RnJURjhKcHZlNEstd21iMzBZR0ZsSndEWE5KVGEtOUhKdDA5SGNSdzYxa1hTOG9UXzFTb003SmYzc1g1cGY5VFdaVXlZMWZLM1hWTWNPenBCS0VuRGhxMFU?oc=5","date":"2026-03-26","type":"pipeline","source":"The Globe and Mail","summary":"Analysts Are Bullish on Top Healthcare Stocks: NRX Pharmaceuticals (NRXP), Rezolute (RZLT) - The Globe and Mail","headline":"Analysts Are Bullish on Top Healthcare Stocks: NRX Pharmaceuticals (NRXP), Rezolute (RZLT)","sentiment":"neutral"},{"date":"2026-03-24","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"date":"2026-02-12","type":"earnings","source":"SEC EDGAR","summary":"10-Q filed with SEC: 10-Q","headline":"Quarterly Report (10-Q) Filed","sentiment":"neutral"},{"date":"2026-02-12","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"date":"2026-01-07","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-12-25","type":"trial","source":"simplywall.st","summary":"Rezolute (RZLT) Valuation Revisited After Phase 3 sunRIZE Trial Misses Primary and Key Secondary Endpoints - simplywall.st","headline":"Rezolute (RZLT) Valuation Revisited After Phase 3 sunRIZE Trial Misses Primary and Key Secondary Endpoints","sentiment":"negative"},{"url":"https://news.google.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?oc=5","date":"2025-12-18","type":"deal","source":"simplywall.st","summary":"Insider Spends US$80k Buying More Shares In Rezolute - simplywall.st","headline":"Insider Spends US$80k Buying More Shares In Rezolute","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMif0FVX3lxTE5RejZ1Ym5nYlZGWXplNF81NmtkWHVSUDNIVWVjRWVjZ1VzbzBKWi1yc1BabzA5eV8zTXAyVzJURnR2NXJWcTdFcHIteFVVWUxTZlRIOU5nTDBFUkhPWG4yY2gwX2kwSnd3ZkhmeklScVRmWHM5bnRUNWhaSVRkT0U?oc=5","date":"2025-12-17","type":"pipeline","source":"Yahoo Finance","summary":"RZLT Stock Plummets 79% Month to Date: Here's What You Need to Know - Yahoo Finance","headline":"RZLT Stock Plummets 79% Month to Date: Here's What You Need to Know","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiugFBVV95cUxPcGVDN3VEOUNnRm5ZRUlmVmZtbUFsLVc5cl9qRVhjcUljOHAwYTRhUHZnUXFMckh0bk1jcVA3NVptZDd1UDR6U1NTTU9WeWtKc3c1OEFuQTVOaHFfNGdkYkc5d1RuWUsySUdualh3WVpaZU5NZktlbHExbk5oNmFXRFFVekMyOXF5VWtBN0p2ZFB1d2lkWE1mWGVIOGJrcHJBdlBPQ1gtWUdHdkF5T2UyTnVfSGVoTlp0alE?oc=5","date":"2025-12-11","type":"trial","source":"Stock Titan","summary":"Rezolute (Nasdaq: RZLT) Phase 3 sunRIZE in HI Misses Primary, Secondary Goals - Stock Titan","headline":"Rezolute (Nasdaq: RZLT) Phase 3 sunRIZE in HI Misses Primary, Secondary Goals","sentiment":"negative"},{"url":"https://news.google.com/rss/articles/CBMi8AFBVV95cUxOS3JaMHQyTDhoeEJaZTV0WktDWDN0TEgwRU9XUWxKN1BTWU9yMEk3MUJpVzc5Z1paTzhtZ3NHNm9WVTZYTkxJSGtlZWtsY0N3aWI5cTdzMmNUZU1GTmVXRW9YVGZzd3FveWlCaFMxU2ljREVlWGFjUlBYMmxtcW82UkpBNGhBM2x5TEZtVlQxdHQ5cTh3N2N2WjlyWUljZWplLXNGc1hLSU90d2hOdE83Uk0ydGZQbW1GM0JkYTJ4blJrXzk2YXcwZ0tMdHYzNGhoc1pENi1VWU53Zk9zZzlpNUZpXy1rVTBlVHZxaC14Sno?oc=5","date":"2025-12-11","type":"trial","source":"proactiveinvestors.com","summary":"Rezolute shares plunge on disappointing Phase 3 congenital hyperinsulinism trial results - proactiveinvestors.com","headline":"Rezolute shares plunge on disappointing Phase 3 congenital hyperinsulinism trial results","sentiment":"negative"},{"url":"https://news.google.com/rss/articles/CBMikAFBVV95cUxNbTVMNnJnNHoxV2l1RTlXaEhIdFRrSWlNbHNObm1CUThOUVQwN3M5N3dxakJyZFlfZlZpcGlBQ09FQzFzX3k0ZUJFVlZXcWJpNk1qczl4TGo4aUdBdUVVZk5vNERYeHpvZzhYck1nNDhxNWdBbmo1ZmxQTXlWOW9wUDQ4Mk81c3VfWFJxN1RCSFo?oc=5","date":"2025-09-17","type":"regulatory","source":"MarketBeat","summary":"Rezolute Stock: FDA Fast Track Fuels 2025 Breakout - MarketBeat","headline":"Rezolute Stock: FDA Fast Track Fuels 2025 Breakout","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisAFBVV95cUxQcXluQ21KNWRmOEpaUUZjZkJCczMza1gzUVQtaEllaHZrQW9zQ2VWazZsSXRYaTlGdVY5SE00bTIyR0FxSmNWSElwN21lay1YZjNkZzcyZ2ZzeVZSdmw1WkNKZEd1b2xjRVc0S0JwNW9qd1BPZlBabzg2aUstbWl0WTduRkV5aDBic1lBM0J1bHNJaWx6NUxPS0RJVWF4X0FaZWpTRnpyZXhzTG80RUdoTg?oc=5","date":"2025-09-16","type":"regulatory","source":"Seeking Alpha","summary":"Rezolute: FDA Pivotal Trial Alignment Change Further Bolsters Ersodetug (NASDAQ:RZLT) - Seeking Alpha","headline":"Rezolute: FDA Pivotal Trial Alignment Change Further Bolsters Ersodetug (NASDAQ:RZLT)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiU0FVX3lxTE5KbUE2dTJhNER3LWZIMkNVZExHR2d4aTVtdjEydG8xNGphR3liVE1qUERWNzhvb0Z6NjBXQ3FERFhqV2lQUTNaaGw1UDNCcktZRHNN?oc=5","date":"2025-04-25","type":"pipeline","source":"Stock Titan","summary":"RZLT Stock Price, News & Analysis - Stock Titan","headline":"RZLT Stock Price, News & Analysis","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinwFBVV95cUxQRndyekpTQ0g1Uk9FcldkVnBUeUk4Mlo0TV8zcGE3VC1WZlp3d09iMDNmWWdHaFZBcVlwa2ZDSlB2d3VNd00yVGpJVDFBZ1FxM0t2cHNaVVRXc3dObnNZaGZuYnFRUFJmSEo1c1ZqVFV0b1B2SzFnOEVSUnhrZUxqQXppOW5BYW1Nb1JDY1RPdlRfNGRsVEItZzRlZVFIQlk?oc=5","date":"2025-02-18","type":"trial","source":"Seeking Alpha","summary":"Rezolute: Late-Stage Study Targeting Hyperinsulinism (NASDAQ:RZLT) - Seeking Alpha","headline":"Rezolute: Late-Stage Study Targeting Hyperinsulinism (NASDAQ:RZLT)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiUEFVX3lxTFBZZWV3SnhocTJValdpV1NyOEl2bll4QlZOTWItTUdQcWJHZTItMG4xbmlOQUpiaDNvN3BtZEZjeVRzOUVFQ1YtYWhFRzh1U0xW?oc=5","date":"2024-03-06","type":"pipeline","source":"CNN","summary":"symbol__ Stock Quote Price and Forecast - CNN","headline":"symbol__ Stock Quote Price and Forecast","sentiment":"neutral"}],"patents":[{"drugName":"RZ358","drugSlug":"congenital-hyperinsulinism-treatment","patentNumber":"","type":"Patent Cliff","expiryDate":"2034-06-01","territory":"US"}],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":2,"keyCompetitors":["BioMarin Pharmaceutical Inc.","Shire plc","Pfizer Inc."],"therapeuticFocus":["Rare Endocrine Disorders","Congenital Hyperinsulinism","Congenital Adrenal Hyperplasia"],"financials":{"source":"sec_edgar+yahoo","revenue":null,"revenuePeriod":null,"revenueHistory":[],"grossProfit":null,"grossProfitHistory":[],"rdSpend":61527000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-74412000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":94107000,"cashHistory":[],"totalAssets":175490000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":null}